Composition, form of production and packaging
? Eye drops in the form of a transparent or slightly opalescent, colorless or slightly colored liquid.
1 ml
hypromellose (hydroxypropylmethylcellulose) 3 mg
Excipients: benzalkonium chloride (100 Ојg / ml), sodium chloride (2 mg / ml), disodium edetate (1 mg / ml), sodium phosphate monobasic dihydrate (3.5 mg / ml), sodium phosphate disubstituted 12-hydroxy (24 mg / ml), water d / u.
10 ml - a bottle-droppers polyethylene (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2010.
PHARMACHOLOGIC EFFECT
Protector of the epithelium of the cornea. Has a moisturizing and protective effect against the cornea with reduced secretion of tear fluid. Possessing high viscosity, increases the duration of contact of the solution with the cornea. The refractive index of the solution is similar to natural tears.
It restores, stabilizes and reproduces the optical characteristics of the tear film.
Subjective and objective improvement of the condition (reduction of hyperemia, epithelialization of lesions) usually occurs within 3-5 days, marked improvement or complete cure - within 2-3 weeks.
PHARMACOKINETICS
Data on the pharmacokinetics of Defisles В® are not available.
INDICATIONS
- erosion and trophic ulcers of the cornea;
- microtraumas of the epithelium of the cornea;
- bullous dystrophic changes of the cornea;
- keratopathy;
- ectropion;
- Lagoftalm;
- deformation of the eyelids;
- condition after plastic operations on the eyelids;
- condition after thermal and chemical burns of the cornea and conjunctiva;
- condition after keratoplasty, keratoectomy;
- Substitution therapy with reduced secretion of tear fluid;
- dry eye syndrome (Sjogren's syndrome), xerosis, keratosis (as part of combination therapy);
- increased sensitivity of the eyes;
- At the end of the diagnostic procedures: gonioscopy, electroretinography, electrooculography, echobiometric examination of the eyeball.
DOSING MODE
The drug should be instilled in 1-2 drops in the conjunctival sac 4-8 times / day. If necessary, you can enter 1-2 drops every hour. The course of treatment is 2-3 weeks.
SIDE EFFECT
Local reactions: the feeling of gluing the eyelids (due to the high viscosity of the solution), allergic reactions.
CONTRAINDICATIONS
- Hypersensitivity to the components of the drug.
It is not recommended to use the drug in the acute phase of the burn (until the complete removal of the toxic substance).
PREGNANCY AND LACTATION
Data on the possibility and safety of use of the drug during pregnancy and lactation there.
SPECIAL INSTRUCTIONS
It is not recommended to wear soft contact lenses during the period of application of the drug. When wearing hard (hard) contact lenses before instilling the drug, they should be removed and reinstalled no earlier than 20-30 minutes after application of the drug.
It is not recommended long-term use of the drug Defisles В® .
Impact on the ability to drive vehicles and manage mechanisms
Immediately after instillation, there may be an unclear visual perception, which can lead to difficulties in driving vehicles or working with mechanisms. Therefore, to start work that requires clarity of vision, should not be earlier than 15 minutes after instillation.
OVERDOSE
When using eye drops, a hypoxic overdose is unlikely.
DRUG INTERACTION
The drug Defisles В® is pharmaceutically incompatible with eye drops containing metal salts.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a place protected from light, inaccessible to children at a temperature of no higher than 25 В° C; Do not freeze. Shelf life - 2 years.
